Literature DB >> 22064394

MS pipeline flowing, but niche remains for neuroprotection.

Hannah Waters.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22064394     DOI： 10.1038/nm1111-1327

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

Authors:  Paul O'Connor; Jerry S Wolinsky; Christian Confavreux; Giancarlo Comi; Ludwig Kappos; Tomas P Olsson; Hadj Benzerdjeb; Philippe Truffinet; Lin Wang; Aaron Miller; Mark S Freedman
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.